Search

Search Constraints

You searched for: Author/Creator Pellicelli, A.

Search Results

1. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C. (February 2020)

2. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance. (February 2019)

3. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy. Issue 1 (February 2018)

4. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents. (10th February 2016)

5. Daclatasvir/sofosbuvir and ribavirin 800 mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience. Issue 1 (16th February 2017)

6. Efficacy of lenvatinib in intermediate stage and advanced hepatocellular carcinoma: Results of monotherapy and combination with locoregional treatment. (March 2023)

7. Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di). (March 2023)

8. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. (17th December 2015)

9. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life. Issue 1 (16th February 2017)

10. HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV sub-genotypes 1 inducing different inflammatory stimuli. (March 2023)